Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

(MedPage Today) -- The FDA on Friday expanded the approval of pirtobrutinib (Jaypirca) in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) to include the first-line treatment of adults whose cancers have no known 17p deletion...

Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Friday 2 October →